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ABSTRACT
Despite increasing amounts of experimental evidence depicting the involvement 
of non-coding RNAs in cancer, the study of BRAFV600E-regulated genes has thus far 
focused mainly on protein-coding ones. Here, we identify and study the microRNAs 
that BRAFV600E regulates through the ERK pathway.
By performing small RNA sequencing on A375 melanoma cells and a vemurafenib-
resistant clone that was taken as negative control, we discover miR-204 and miR-211 
as the miRNAs most induced by vemurafenib. We also demonstrate that, although 
belonging to the same family, these two miRNAs have distinctive features. miR-204 is 
under the control of STAT3 and its expression is induced in amelanotic melanoma cells, 
where it acts as an effector of vemurafenib’s anti-motility activity by targeting AP1S2. 
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Conversely, miR-211, a known transcriptional target of MITF, is induced in melanotic 
melanoma cells, where it targets EDEM1 and consequently impairs the degradation 
of TYROSINASE (TYR) through the ER-associated degradation (ERAD) pathway. In 
doing so, miR-211 serves as an effector of vemurafenib’s pro-pigmentation activity. 
We also show that such an increase in pigmentation in turn represents an adaptive 
response that needs to be overcome using appropriate inhibitors in order to increase 
the efficacy of vemurafenib.
In summary, we unveil the distinct and context-dependent activities exerted 
by miR-204 family members in melanoma cells. Our work challenges the widely 
accepted “same miRNA family = same function” rule and provides a rationale for a 
novel treatment strategy for melanotic melanomas that is based on the combination 
of ERK pathway inhibitors with pigmentation inhibitors.
INTRODUCTION
BRAF is a Ser/Thr protein kinase belonging to the 
highly oncogenic RAS/RAF/MEK/ERK signaling pathway. 
Roughly half of melanomas harbor somatic mutations 
in BRAF. The most frequent mutation is the V600E 
substitution, which renders the kinase constitutively active as 
a monomer and independent of RAS-induced dimerization 
[1]. Identification of this driver mutation has paved the way 
for development of selective molecularly-targeted inhibitors. 
BRAFi such as vemurafenib have been shown to increase 
overall and progression-free survival in metastatic melanoma 
patients who carry the V600E mutation. However, these 
inhibitors have significant limitations, including: suboptimal 
response rates, which occur in setting of adaptive cellular 
responses [2–6]; a heterogeneous response rate among 
patient populations; severe side effects that often require 
treatment termination; invariable development of acquired 
resistance within 6 months of treatment initiation [7, 8]. 
Therefore, novel approaches to enhance BRAFi efficacy are 
still needed [9, 10].
In order to improve BRAFV600E targeting, it is 
vital to gain a deeper understanding of the genes that are 
positively and negatively regulated by this kinase. In this 
work we focus on the identification and characterization 
of BRAFV600E-regulated microRNAs (miRNAs). While 
protein-coding genes have been extensively studied, the 
reported cases of non-coding RNAs that BRAFV600E 
regulates through the ERK pathway are still very few (the 
long non-coding RNA BANCR (BRAF-activated lncRNA), 
miR-146a and miR-768-3p are among the few examples 
[11–13]). In contrast, all classes of long and short non-
coding RNAs have recently come to the forefront as 
crucial regulators of gene expression that play a pivotal 
role in human cancer [14, 15]. There are also examples 
of miRNAs being used as drugs or drug targets [16]. 
Therefore, the thorough study of BRAFV600E-regulated 
miRNAs is relevant not only in regards to basic RNA 
biology, but also for its potential translational implications.
Through use of high-throughput techniques such as 
the sequencing of small RNAs, we were able to identify 
the full spectrum of miRNAs that in melanoma are 
regulated by BRAFV600E through the ERK pathway. We 
then focused on the miRNA family composed by miR-
204 and miR-211 and investigated their transcriptional 
regulation, respective functions and how they interact 
with vemurafenib. Ultimately, the analysis allowed us 
to demonstrate that miRNAs belonging to the same 
family can exert distinct biological roles. Furthermore, 
we discovered a novel adaptive mechanism in melanotic 
melanomas, which is elicited by BRAFi/MEKi and needs 
to be overcome in order to fully unleash their activity.
RESULTS
miR-204 is induced by vemurafenib in A375 
melanoma cells
In order to identify the miRNAs that are positively 
and negatively regulated by BRAFV600E through the 
ERK pathway, we took three sensitive cell lines that carry 
the V600E mutation (A375, 501 Mel and SK-Mel-28) and 
used them to generate individual clones and populations that 
are resistant to the selective BRAF inhibitor vemurafenib 
(PLX4720, Supplementary Figure 1-4 and Supplementary 
Table 1, 2). These resistant lines are characterized by 
mechanisms of acquired resistance (AR) that, although 
different, all lead to the reactivation of the ERK pathway 
(Figure 1a). Specifically, A375 C1, C2, C3 resistant clones 
and A375 P1 resistant population carry a BRAF splicing 
variant (Figure 1b–1c); A375 P2 resistant population carries 
a K117N mutation on KRAS gene (Figure 1d); 501 Mel P1 
resistant population carries a BRAF splicing variant (Figure 
1e, 1f); Sk-Mel-28 C1 and C2 resistant clones show the 
over-expression of EGFR and PDGFRbeta (Figure 1g)
We then performed RNA-sequencing of small RNAs 
(miRNA-seq) comparing four conditions: parental A375 
sensitive cells treated with DMSO or 2uM vemurafenib 
and A375 C2 resistant clone treated with DMSO or 2uM 
vemurafenib (Figure 2a, Supplementary Figure 5 and 
Supplementary Table 3-5). Clustering analysis indicated that 
the only condition that is different from the others is the one 
in which vemurafenib is able to inhibit BRAFV600E and 
block the ERK pathway in A375 parental cells (Figure 2b).
Based on these results, we selected as BRAFV600E-
regulated miRNAs those that showed increased or 
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Figure 1: Mechanisms of acquired resistance displayed by vemurafenib-resistant clones and populations obtained from 
A375, 501 Mel and SK-Mel-28 cells. (a) Table that lists vemurafenib-resistant clones (C) and populations (P) and the corresponding 
resistance mechanism. The full list of known alterations that were searched for is reported in Supplementary Table 2. The resistance mechanism 
of SK-Mel-28 P1 population remains to be discovered. (b) Western blot for BRAFV600E protein in A375 parental cell line and vemurafenib-
resistant clones (C) and populations (P). SK-Mel-197 cells, which are wt for BRAF, are included as a negative control. Immunoblotting for 
α-TUBULIN (TUB) is used as loading control. (c) Cartoon depicting the BRAFV600E splicing variants identified in A375 vemurafenib-resistant 
clones and populations. RBD: RAS-binding domain. (d) Electropherograms showing a single-nucleotide mutation (A→C) in the KRAS gene of 
A375 P2 resistant population (right) compared to A375 parental cell line (left), resulting in the K117N amino acid substitution. (e) Western blot 
for BRAFV600E protein in 501 Mel parental cell line and vemurafenib-resistant population (P1). SK-Mel-197 cells, which are wt for BRAF, are 
included as negative control. Immunoblotting for α-TUBULIN (TUB) is used as loading control. (f) Cartoon depicting the BRAFV600E splicing 
variant identified in 501 Mel P1. (g) In SK-Mel-28 C1 and C2 vemurafenib-resistant clones, EGFR and PDGFRβ are over-expressed, as detected 
by real-time PCR. The graphs represent the mean±SEM of 3 independent experiments. *p<0.05, **p<0.01.
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Figure 2: Identification of miR-204 as a microRNA regulated by BRAFV600E through the ERK pathway. (a) Experimental 
design of miRNA-seq. A375 parental cell line and A375 C2 vemurafenib-resistant clone were treated with vehicle (DMSO) or 2uM 
vemurafenib for 48h. RNA was extracted and used to perform the miRNA-seq. (b) Sample clustering based on the distance matrix of miRNA 
profiles. Euclidean metric was used to measure the distance between samples. Darker blue represents higher similarity. (c) Heatmap of 
differentially expressed miRNAs. Variance-stabilized transformed count data is scaled and centered. (d) Dotplot of the miRNAs differentially 
expressed in A375 vemurafenib vs A375 DMSO (upper) and in C2 vemurafenib vs C2 DMSO (lower). (e) miR-204 reads obtained from 
miRNA-seq, relative to control (A375 treated with DMSO). In both (d) and (e), the graphs show that miR-204 levels are induced in A375 
vemurafenib, but not in C2 vemurafenib. (f) (left) Sequence of miR-204 family members, miR-204 and miR-211. The sequence of the 
“miR-204 family” real-time PCR primer is also reported. (right) Schematic representation of miR-204 and miR-211 host genes (TRPM3 
and TRPM1, respectively). Red and blue rectangles: exons; dashed lines: other exons/introns; arrows: host gene-specific real-time PCR 
primers. (g) Time course of miR-204 expression levels after the gene-expression inhibition of BRAF by siRNA. (h) miR-204 levels after 48h 
of treatment with 2uM vemurafenib in cells stably expressing the BRAFV600E Δ [3–10] splicing variant compared to the empty vector. (i) 
miR-204 expression levels in A375 parental cell line and C2 and P2 vemurafenib-resistant derivatives after treatment with 2uM vemurafenib 
or 1nM trametinib for 48h. Vemurafenib and trametinib treatments are normalized on the control samples (DMSO, dotted line). The graphs 
represent the mean±SEM of 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001.
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decreased expression levels in A375 cells treated with 
vemurafenib and comparable levels in the other three 
conditions. By following the sequential steps summarized 
in Supplementary Figure 5b, we identified 53 miRNAs, of 
which 28 are induced and 25 are repressed by vemurafenib 
(Figure 2c). Among the 28 induced miRNAs, we selected 
miR-204-5p (miR-204), as it is the most induced one 
among those highly expressed (Figure 2d, 2e). According 
to our miRNA-seq results, this miRNA comes in two 
isomiRs, one that corresponds to the canonical 22nt 
sequence and the other that is 1nt longer at the 3’end 
(Supplementary Figure 6a). Furthermore, it is in the same 
family as miR-211-5p (miR-211, Figure 2f, left), which 
is not expressed in A375 cells, according to our miRNA-
seq experiment and confirmed by previous studies [17]. 
Both miRNAs are intronic (they are hosted in intron 6 
of TRPM3 (miR-204) and TRPM1 (miR-211) (Figure 2f, 
right)) and are co-expressed with their host genes [18, 19].
Since miR-204 and miR-211 have very similar 
sequences, the measurement of their individual levels by 
real-time PCR can be technically difficult. Therefore, we 
developed 2 alternative strategies: firstly, we designed a 
primer that measures their cumulative levels (miR-204 
family primer, Figure 2f, left); secondly, in order to assess 
individual contributions, we opted for measuring the levels 
of the host genes using TRPM3- and TRPM1-specific 
primers (Figure 2f, right).
The ability of vemurafenib to induce miR-204 
and TRPM3 in A375 cells was confirmed by performing 
real-time PCR on the same samples used for the miRNA-
seq (Supplementary Figure 6b, 6c), as well as using the 
array data reported in ref [20] (Supplementary Figure 
6d). Furthermore, a time-course experiment allowed us 
to establish that the induction of miR-204 starts 24h after 
vemurafenib treatment initiation and reaches its plateau at 
48h (Supplementary Figure 6e). Finally, a dose response 
curve indicated that vemurafenib administered at as low as 
0.02uM is sufficient to induce miR-204 (Supplementary 
Figure 6f).
miR-204 is negatively regulated by BRAFV600E 
through the ERK pathway
In order to confirm that the induction of miR-204 is 
a consequence of the selective inhibition of BRAFV600E 
caused by vemurafenib and not an off-target effect, we 
performed several experiments. First, we observed that, 
similarly to the chemical inhibition through vemurafenib, 
the knock-down of BRAF through RNA interference 
causes an induction of miR-204 levels in A375 cells 
(Figure 2g and Supplementary Figure 7a, 7b). Second, 
we infected A375 cells with the BRAFV600EΔ [3–10] 
splicing variant, which is found in the A375 C2 clone 
(Figure 1a-1c). In agreement with the data reported 
by Basile and colleagues [21], the expression of this 
variant was sufficient to render A375 cells insensitive to 
vemurafenib (Supplementary Figure 7c-7e), and moreover 
it prevented the induction of TRPM3 miR-204 upon 
vemurafenib treatment (Figure 2h and Supplementary 
Figure 7f). Third, in MeWo and SK-Mel-197 cells, which 
are BRAF wild-type and hence insensitive to BRAFi, 
we did not observe any induction of the miR-204 family 
upon vemurafenib treatment (Supplementary Figure 8a). 
Comparably, we found that miR-204 is not induced upon 
treatment of A375 cells with dacarbazine, an alkylating 
agent with a distinct mechanism of action compared to 
vemurafenib (Supplementary Figure 8b, 8c).
Next, we assessed whether the induction of 
miR-204 caused by vemurafenib can be attributable to 
blocking of the ERK signaling pathway. To this end, 
we examined the A375 C2 clone and the A375 P2 
population. Both these resistant lines are insensitive to 
vemurafenib due to the reactivation of the ERK pathway, 
but the alterations that they carry are different (Figure 
1a-1d). Consistent with the hypothesis that inhibition 
of the ERK pathway is crucial in the induction of 
miR-204, both the C2 and the P2 cells were unable to 
induce the miRNA upon vemurafenib treatment (Figure 
2i and Supplementary Figure 9a). We then inhibited 
the pathway one step downstream of BRAF using the 
MEK inhibitor trametinib and found that miR-204 is 
induced in A375 cells that are sensitive to this drug and 
in the A375 C2 clone, which, although being resistant 
to vemurafenib, retains sensitivity to MEKi. Conversely, 
the P2 population, which is cross-resistant to MEKi, 
did not show any induction of miR-204 not only when 
treated with vemurafenib, but also when treated with 
trametinib (Figure 2i, Supplementary Figure 9b, 9c and 
refs [22, 23]).
Altogether, the data presented thus far indicate that 
miR-204 is negatively regulated by BRAFV600E through 
the ERK pathway and is induced by BRAFi/MEKi.
BRAFi/MEKi induce miR-204 and miR-211 in a 
mutually exclusive fashion
Since miR-204 and miR-211 belong to the same 
family, we tested whether the inhibition of the ERK 
pathway causes miR-211 induction as well. Indeed, 
we found that in melanoma cell lines carrying the 
BRAFV600E mutation (WM266-4, SK-Mel-28, 501 
Mel, SK-Mel-5 and WM35 in Figure 3a) treatment with 
both vemurafenib and trametinib does cause TRPM1 
induction. In melanoma cell lines that are wild type for 
BRAF (MeWo and SK-Mel-197 in Figure 3a) trametinib 
treatment also causes TRPM1 induction. Furthermore, 
we found that, in vemurafenib-resistant cells such as 
501 Mel P1 and SK-Mel-28 C2, TRPM1 basal levels are 
comparable to those of parental cells and fail to be induced 
upon vemurafenib/trametinib treatment (Figure 3a; see 
also ref [24]). These data suggest that TRPM1 and TRPM3 
induction share common features.
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Figure 3: Induction of TRPM3/miR-204 and TRPM1/miR-211 upon treatment of melanoma cell lines and metastatic 
melanoma patients with BRAFi and/or MEKi. (a) Fold induction of miR-204 family, TRPM1 and TRPM3 upon 48h of 2uM 
vemurafenib (V, upper) or 1nM trametinib treatment (T, lower) of the indicated BRAFV600E and wt BRAF (underlined) melanoma cell 
lines. Vemurafenib-resistant clones and populations are used as negative controls (when the drugs cannot function, there is no miRNA 
induction). D: DMSO. The expression levels of miR-204 family, TRPM1 and TRPM3 in each parental line treated with DMSO is taken as 
baseline and used as normalization control. Fold changes are therefore represented as increases over the baseline (a darker color means a 
higher fold change). (b-d) Expression levels of TRPM1 (blue) and TRPM3 (red) in bioptic samples collected from metastatic melanoma 
patients at 3 time points: before the beginning of the treatment (pre), early on during treatment (EDT) and at progression (progr). (b) In the 
GSE 50509 dataset, patient #10 was treated with the BRAFi dabrafenib and 2 different tumor sites were analyzed at progression. (c) In the 
GSE 61992 dataset, patient #1 was treated with the BRAFi dabrafenib and the MEKi trametinib. (d) In the EGAS00001000992 dataset, 
patients #6, #10 and #16 were treated with the BRAFi dabrafenib and the MEKi trametinib, while patient #24 was treated with the BRAFi 
vemurafenib.
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miR-211 induction was confirmed in vivo by 
analyzing TRPM1 levels in tumor biopsies obtained 
from patients with metastatic melanoma who eventually 
progressed on treatment with BRAFi and/or MEKi. 
Biopsies were collected at three time points: before the 
beginning of the treatment (pre), early on during treatment 
(14-16 days after the beginning of the treatment, EDT) 
and at resistance (when the disease starts to progress on 
treatment, progr). Out of a total of 14 cases belonging to 
three different datasets (GSE 50509 (n=2), GSE 61992 
(n=1), EGAS00001000992 (n = 11, [4])), six were found 
to display the expected trend in TRPM1 expression: 
induction early on during treatment (EDT), decrease to 
basal levels at time of resistance (progr) (Figure 3b, blue 
lines).
After establishing that TRPM3/miR-204 and 
TRPM1/miR-211 are both induced by BRAFi and MEKi, 
we tested whether they are co-induced or not. We looked 
for a positive correlation in the expression levels of 
TRPM1 and TRPM3 in the melanoma cases profiled by 
microarray in ref [25] (n=45), ref [26] (n=56), ref [27] 
(n=28), ref [28] (n=214) and at www.cbioportal.org, 
however no correlation was discovered (Supplementary 
Figure 10a-10e, left panels and Supplementary Table 
6). Furthermore, using melanoma cell lines and patients 
data, we found that the induction of the two miRNAs is 
in fact mutually exclusive. Namely, when both TRPM3/
miR-204 and TRPM1/miR-211 are expressed, TRPM1/
miR-211 is the only one that gets induced (refer to 501 
Mel, SK-Mel-5, WM35, MeWo and SK-Mel-197 in 
Figure 3a and to Figure 3b-3d). Conversely, TRPM3/miR-
204 is induced when it is the only one expressed (refer to 
A375 and WM278 in Figure 3a). These results suggest 
that, downstream of the ERK pathway, the transcriptional 
regulation of the two miRNAs is different.
miR-211 is under the transcriptional control of 
MITF and miR-204 is under the transcriptional 
control of STAT3
The transcriptional regulation of TRPM1/miR-211 
has been extensively studied. As a melanocytic lineage-
specific miRNA (Supplementary Figure 11a) miR-211 is a 
well-established transcriptional target of MITF, the master 
regulator of the melanocytic lineage (see Supplementary 
Figure 10a-10e, middle panels, where the positive 
correlation between TRPM1 and MITF levels is shown; 
see also, for example, ref [29]). In turn, MITF is inhibited 
by the ERK pathway and hence activated by vemurafenib 
[3, 30]. Consistent with these findings, we observed that 
upon treatment with vemurafenib, TRPM1 is induced 
with other genes that belong to the “MITF signature” 
(Supplementary Figure 12a). Furthermore, we were able 
to demonstrate that the vemurafenib-mediated induction 
of TRPM1 is in fact MITF-dependent, by showing that 
in 501 Mel, SK-Mel-5 and WM35 cells it is prevented by 
the knock-down of MITF mediated by siRNA transfection 
(Figure 4a and Supplementary Figure 12b, 12c).
In light of the mutually exclusive induction of 
TRPM1/miR-211 and TRPM3/miR-204 upon treatment 
with vemurafenib/trametinib, our first step in the analysis 
of TRPM3/miR-204 transcriptional regulation was to 
examine the involvement of MITF. We discovered that 
contrary to the melanocytic lineage restricted expression 
of miR-211, miR-204 expression is much more widespread 
(Supplementary Figure 11b). Furthermore, we could not 
find a correlation between MITF and TRPM3 levels in any 
of the datasets analyzed (Supplementary Figure 10a-10e, 
right panels). It was also noted that MITF levels are much 
lower in the cell lines where TRPM3/miR-204 is induced 
compared to those where TRPM1/miR-211 is induced 
(Supplementary Figure 13). Finally, we demonstrated 
that the induction of TRPM3/miR-204 upon vemurafenib 
treatment is not MITF-mediated by showing that it is not 
impaired by si-MITF (Figure 4b; see also ref [31]).
Once MITF was ruled out, we looked for other 
candidates that could serve as possible links between 
TRPM3/miR-204 and the ERK pathway. It has been 
recently shown that in melanoma cells the inhibition 
of the ERK pathway can cause the activation of STAT3 
[32–35]. Furthermore, STAT3 binding sites have been 
identified within the TRPM3 genomic locus [36]. 
Therefore, we assessed whether TRPM3/miR-204 
induction occurs through STAT3. We observed that 
upon vemurafenib and trametinib treatment, STAT3 
is phosphorylated in the cells where TRPM3 and miR-
204 are induced (i.e. A375 and WM278) but not in 
those where they are not induced (i.e. 501 Mel and 
WM35) (Figure 4c and Supplementary Figure 12d, 
12e). Moreoever, we established that the co-treatment 
of A375 cells with the selective STAT3 inhibitor S3I-
201 abolishes the upregulation of TRPM3/miR-204 
induced by vemurafenib and trametinib (Figure 4d, 4e 
and Supplementary Figure 14a).
Additionally, this effect was detected by means of a 
miR-204 sensor in which the expression of the mCherry 
reporter is inversely proportional to miR-204 levels, while 
the levels of the eYFP reporter are used as a normalizer 
(Supplementary Figure 15a-15d). We found that the 
vemurafenib-induced increase in endogenous TRPM3/
miR-204 levels in turn causes a decrease in mCherry 
fuorescence (Figure 4f) and mCherry/eYFP mRNA ratio 
(Figure 4g). However, when vemurafenib is combined 
with S3I-201, the induction is blunted and mCherry levels 
are restored (see also Supplementary Figure 15e).
Finally, we aimed to identify the upstream 
regulator of STAT3. We tested whether the induction of 
TRPM3/miR-204 caused by vemurafenib is reversed by 
the concomitant treatment with inhibitors of JAK2, SRC 
or PI3K respectively, which are all well-known STAT3 
activators [32, 34, 35, 37]. As shown in Supplementary 
Figure 14b-14d, we found that the JAK2/STAT3 
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Figure 4: Upon treatment with vemurafenib or trametinib, TRPM1/miR-211 induction is MITF-dependent, while 
TRPM3/miR-204 induction is STAT3-dependent. (a) si-MITF prevents TRPM1/miR-211 induction upon vemurafenib treatment in 
501 Mel cells. The cells were transfected with si-CT or si-MITF and 24h later they were exposed to vehicle (DMSO) or 2uM vemurafenib 
for additional 48h. (b) si-MITF does not prevent TRPM3/miR-204 induction upon vemurafenib treatment in A375 cells. The cells were 
transfected with si-CT or si-MITF and 24h later they were exposed to vehicle (DMSO) or 2uM vemurafenib for additional 48h. (c) Upon 
48h of treatment with 2uM vemurafenib, STAT3 phosphorylation is induced in A375 and WM278 cells (left), but not in 501 Mel and WM35 
cells (right). (d-e) The induction of TRPM3/miR-204 caused by 48h treatment with 2uM vemurafenib (d) or 1nM trametinib (e) is impaired 
by the concomitant treatment with 4uM of the STAT3 inhibitor S3I-201. (f-g) A375 cells that stably express the inducible pTRE-TIGHT-
BI-RY miR-204 sensor were treated with 2uM vemurafenib ± 4uM S3I-201 for 48h and then with 2 ug/ml doxycycline for additional 48h. 
Upon vemurafenib treatment, the increase in endogenous TRPM3/miR-204 levels causes a decrease in mCherry fluorescence (f), as well 
as in the mCherry/eYFP ratio (g). Upon the combined vemurafenib plus S3I-201 treatment, TRPM3/miR-204 induction is blunted and 
mCherry protein and mRNA return to basal levels. The graphs represent the mean±SEM of 3 independent experiments. *p<0.05, **p<0.01, 
***<0.001.
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double inhibitor WP1066 is able to inhibit STAT3 
phosphorylation and reverse miR-204 induction upon 
vemurafenib treatment, while the JAK2 single inhibitor 
AZD1480 (Supplementary Figure 14e-14g), the SRC 
inhibitor PP1 and the PI3K inhibitor wortmannin are 
not (Supplementary Figure 14h). Taken together, these 
results indicate that, downstream of the ERK pathway, 
the transcriptional regulation of miR-204 and miR-211 
is different, with the latter being under the control of 
MITF, while the former is under the control of STAT3. 
The data also suggest-that JAK2, SRC and PI3K are all 
dispensable for the ERK pathway-dependent STAT3 
activation [33].
miR-204 mediates the anti-motility activity of 
vemurafenib in amelanotic melanoma cells
In order to study the biological effects of miR-204 
and miR-211 induction upon vemurafenib/trametinib 
treatment, we used the biological context in which this 
induction actually happens. Specifically, we discovered 
that the cell lines where TRPM3/miR-204 is induced are 
amelanotic (A375, WM278 and SK-Mel-2 in Figure 3a), 
while the cell lines where TRPM1/miR-211 is induced 
are melanotic (501 Mel, SK-Mel-5, WM35, MeWo and 
SK-Mel-197 in Figure 3a). Interestingly, WM266-4 and 
SK-Mel-28, the two cell lines where TRPM3/miR-204 
and TRPM1/miR-211 are co-induced, are in fact “hybrid” 
cell lines, because they are not pigmented and yet 
contain melanosomes [38, 39]. Therefore, we focused on 
amelanotic and melanotic cells for the study of miR-204 
and miR-211, respectively.
miR-204 has been shown to inhibit cell motility in 
many tumor types and the ability of miR-211 to inhibit 
cell motility in melanoma is well established (please, refer 
to Supplementary Table 7 for references). Furthermore, 
vemurafenib itself is known to negatively affect the 
motility of melanoma cells [40]. Therefore, we evaluated 
whether miR-204 acts as an effector of the anti-motility 
activity exerted by BRAFi and MEKi on melanoma cells. 
Using a wound healing assay, we found that, similarly 
to the over-expression of miR-211 which was taken as 
positive control, the over-expression of miR-204 does 
cause an impairment in the ability of A375 melanoma 
cells to migrate (Figure 5a, 5b and Supplementary Figure 
16a, 16b).
We also discovered that miR-204 over-expression 
potentiates the activity of vemurafenib in A375 cells 
(Figure 5c, 5d), as well as trametinib in SK-Mel-2 cells 
(Supplementary Figure 17a). Remarkably, miR-204 
over-expression causes a decrease in cell motility even 
in vemurafenib-resistant A375 C2 cells (Figure 5e). 
However, in this setting the potentiation in presence of 
vemurafenib is not observed, which confirms that it 
depends on the induction of endogenous miR-204 levels 
by the drug.
The evidence that vemurafenib relies on miR-204 
in order to exert its anti-motility activity was obtained 
in a miR-204 knock-down experiment performed by 
taking advantage of the CRISPR-Cas9 technology. An 
sgRNA that targets the Cas9 enzyme against the loop of 
pre-miR-204 was used to disrupt the miR-204 gene and 
subsequently cause dowregulation of the endogenous 
mature miRNA levels (Supplementary Figure 18). In this 
genetic context, we found that the ability of A375 cells to 
migrate is increased (in Figure 5f, compare DMSO-treated 
A375-miR-204 sgRNA cells with DMSO-treated A375-
AVV1 sgRNA control cells) and that the anti-motility 
effect of vemurafenib is blunted (in Figure 5f compare 
vemurafenib-treated A375-miR-204 sgRNA cells with 
vemurafenib-treated A375-AVV1 sgRNA control cells).
The negative effects of miR-204 on melanoma 
cell motility were further confirmed using a different 
assay. As shown in Figure 5g, 5h for A375 cells, and in 
Supplementary Figure 17b, 17c for WM278 and SK-
Mel-2 cells, we found that the over-expression of miR-204 
decreases the ability of melanoma cells to invade across 
matrigel-coated filters in a transwell assay and potentiates 
vemurafenib/trametinib effects. Contrary to migration/
invasion, the over-expression of miR-204 has no effect on 
the short- and long-term growth of A375 cells nor their 
ability to form colonies. Furthermore, it does not show any 
cooperation with vemurafenib (Supplementary Figure 19).
miR-204 targets AP1S2
Next, we sought to determine the molecular target 
through which miR-204 negatively affects melanoma cell 
motility. We detected several validated miR-204/miR-
211 pro-motility targets (Supplementary Table 7) and we 
found a subgroup, namely AP1S2, EZRIN, RAB22A and 
TGFbetaR2 that exhibit a decrease in expression upon 
transfection of A375 cells with si-miR-204 (204-mimic) 
and si-miR-211 (211-mimic) (Supplementary Figure 16c 
and 20). We then uncovered that, when the over-expression 
of miR-204 is combined with vemurafenib treatment, 
the RNA levels of the aforementioned target genes - and 
especially of AP1S2 - show a further decrease (Figure 6a). 
Therefore, they represent likely candidates to explain the 
cooperation between miR-204 and vemurafenib.
Then, we focused on AP1S2 (Adaptor Related 
Protein Complex 1 Sigma 2 Subunit) and we found that 
its knock-down by means of an siRNA (si-AP1S2) is able 
to phenocopy the effect of 204-mimic on migration and its 
cooperation with vemurafenib (Figure 6b).
Finally, we demonstrated that AP1S2 is the target 
through which miR-204 exerts its anti-motility activity. 
We established that the decrease in migration (Figure 
6c) and invasion (Figure 6d) caused by miR-204 over-
expression is blunted by the concomitant over-expression 
of the miRNA-insensitive AP1S2 open reading frame 
(ORF). Conversely, we showed that the increase in 
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Figure 5: miR-204 mediates the anti-motility activity of vemurafenib in amelanotic melanoma cells. (a-b) Wound closure 
of A375 cells that stably over-express a control miRNA (p-miR-CT, black), miR-204 (p-miR-204, red) or miR-211 (p-miR-211, blue). 
(c-d) Wound closure of A375 cells that stably over-express a control miRNA (p-miR-CT, black), miR-204 (p-miR-204, red) or miR-211 
(p-miR-211, blue) and were treated for the indicated time points with vehicle (DMSO) or 2uM vemurafenib. Before being subjected to the 
assay, the cells were pretreated with vemurafenib for additional 24h. (e) Wound closure of A375 C2 vemurafenib-resistant cells that were 
transiently transfected with si-CT (black and grey) or 204-mimic (red and dark red), treated with vehicle (DMSO) or 2uM vemurafenib 
for 24h and then subjected to the wound healing assay for the indicated time points. (f) Wound closure of A375 cells that stably express 
a control AVV1 sgRNA (black) or a miR-204 sgRNA (red) and that were treated for the indicated time points with vehicle (DMSO) or 
2uM vemurafenib. The cells were pretreated for 72h with doxycycline in order to induce the expression of Cas9 and hence the disruption 
of miR-204 gene, with the consequent dowregulation of the endogenous mature miRNA levels. (g-h) Matrigel invasion assay performed 
on A375 cells that stably over-express a control miRNA (p-miR-CT, white and black) or miR-204 (p-miR-204, red and dark red) and 
that were treated with 2uM vemurafenib for 6h. The graphs represent the mean±SEM of 3 independent experiments. *p<0.05, **p<0.01, 
****<0.0001.
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migration caused by miR-204 down-regulation is blunted 
by the concomitant knock-down of AP1S2 (Figure 6e).
Clinically, the oncosuppressive role played by 
miR-204 in melanoma cells through its ability to impair 
cell motility is further supported by the GSE 19234 
dataset [41], where metastatic melanoma patients 
with high TRPM3/AP1S2 ratio show a trend toward 
higher overall survival compared to those with low 
TRPM3/AP1S2 ratio (Figure 6f and Supplementary 
Figure 21).
Altogether these results indicate that, in amelanotic 
melanoma cells, miR-204 is induced by BRAFi/MEKi and 
favors its anti-migratory activity by targeting AP1S2.
miR-211 mediates the pro-pigmentation activity 
of vemurafenib in melanotic melanoma cells
We mentioned above that the cell lines where miR-
211 is induced by vemurafenib (501 Mel, Sk-Mel-5 and 
WM-35) and trametinib (MeWo and SK-Mel-197) (Figure 
Figure 6: miR-204 inhibits motility by targeting AP1S2. (a) AP1S2, EZRIN, RAB22A and TGFbetaR2 levels in A375 cells that 
stably over-express a control miRNA (p-miR-CT) or miR-204 (p-miR-204) and were exposed to vehicle (DMSO) or 2uM vemurafenib for 
24h. (b) Wound closure of A375 cells transfected with si-CT (black), 204-mimic (red) or si-AP1S2 (green) and then treated for the indicated 
time points with vehicle (DMSO) or 2uM vemurafenib, after 24h of pretreatment with the same drug. (c) Wound closure of A375 cells that 
were stably infected with PIG empty vector (PIG) or PIG-AP1S2 and transfected with si-CT or 204-mimic. (d) Matrigel invasion assay 
performed on A375 cells that were stably infected with PIG empty vector (PIG) or PIG-AP1S2, then transfected with si-CT or 204-mimic 
and finally allowed to invade for 6h. (e) Wound closure of A375 cells that stably express a control AVV1 sgRNA or a miR-204 sgRNA and 
transfected with si-CT or si-AP1S2. The cells were pretreated for 72h with doxycycline in order to induce the expression of Cas9 and hence 
the disruption of miR-204 gene, with the consequent down-regulation of the endogenous mature miRNA levels. (f) Above the median (red) 
and below the median (black) TRPM3/AP1S2 ratios allow to stratify metastatic melanoma patients according their overall survival (GSE 
19234). The graphs represent the mean±SEM of 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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3a) are melanotic. Furthermore, miR-211 has been recently 
reported to promote the pigmentation of mouse melanoma 
cells [42]. As it is already known that vemurafenib itself 
causes an increase in the pigmentation of melanoma cells 
[3], we sought to determine if miR-211 is an effector of the 
pro-pigmentation activity exerted by BRAFi and MEKi.
The transient transfection of its mimic in 501 Mel 
cells allowed us to show that miR-211 over-expression 
causes an increase in pigmentation (Figure 7a, 1 vs 3 
and Supplementary Figure 22a, 22b), which, according 
to electron microscopy, is due to an increase in the total 
number of melanosomes (Figure 7b, i vs iii and Figure 
7c). We also observed that miR-211 over-expression 
strongly potentiates the pigmentation that is induced by 
vemurafenib (Figure 7a, 2 vs 4, Figure 7b, ii vs iv and 
Figure 7c). Specifically, it causes an increase in the 
number of heavily pigmented stage IV melanosomes 
(Figure 7d). This effect is not due to off-targeting, as it 
is reverted by the co-transfection of 211-mimic with 
the corresponding LNA (Supplementary Figure 22c). 
Furthermore, it can be observed in other melanotic cell 
lines treated with vemurafenib (such as SK-Mel-5, 
Supplementary Figure 22e), as well as in 501 Mel and 
SK-Mel-5 cells treated with trametinib (Supplementary 
Figure 22f, 22g). Conversely, when endogenous miR-
211 activity is inhibited by LNA, then both the basal 
and the vemurafenib-induced increase in pigmentation is 
heavily affected (Figure 7e). These results indicate that 
vemurafenib does rely on miR-211 in order to exert its 
pro-pigmentation activity and prompted us to identify the 
molecular mediators.
miR-211 targets EDEM1
In mouse melanoma cells miR-211 acts by 
increasing the mRNA and subsequently protein levels of 
Tyrosinase (Tyr) and Tyrosinase-Related Protein 1 (Tyrp1), 
two enzymes involved the biosynthesis of melanin 
pigment [42]. Therefore, we questioned whether it has a 
similar mode of action in human cells. Upon the treatment 
of 501 Mel cells with vemurafenib, we found that TYR is 
induced at the transcriptional level. This result is expected, 
given that this gene is under the transcriptional control 
of MITF, which is in turn activated by vemurafenib [3, 
30, 43]. However, upon 211-mimic transfection there is 
a further increase in TYR expression that occurs only at 
the protein level, a result that is not in agreement with 
the data obtained in the mouse model (Figure 7f, 7g and 
Supplementary Figure 22h). Consistently, the inhibition of 
endogenous miR-211 by means of LNA-211 results in a 
decrease in TYR protein levels, while the mRNA levels 
remain unaltered (Figure 7h, 7i).
In order to identify the target used by miR-211 
to increase TYR expression at the post-transcriptional 
level, we performed an mRNA array. We transfected 501 
Mel cells with the control siRNA (si-CT), 211-mimic, or 
204-mimic for 24h and then tested them with the Illumina 
ht12_V4 array. Although in melanotic cells miR-204 
is not induced by vemurafenib/trametinib (see Figure 
3a), its over-expression affects pigmentation in a very 
similar manner to that of miR-211, both at the cellular 
(Figure 7a, Supplementary Figure 22a, 22b, 22d) and at 
the molecular level (Figure 7f, 7g and Supplementary 
Figure 22h). Therefore, in this experiment we used 
it to gain stringency during the identification of the 
direct targets of miR-211 that can account for its pro-
pigmentation activity. After confirming that the signature 
of differentially expressed mRNAs is consistent with 
miR-211 and miR-204 activity (Supplementary Figure 
23), we focused on the 81 mRNAs that were differentially 
expressed upon the transfection of both mimics (Figure 
7j, left, Supplementary Table 8, 9). In accordance with 
the biological effect described above, GO-enrichment 
analysis highlighted “protein transport/response to 
endoplasmic reticulum stress/regulation of translation” 
among the most enriched categories (Figure 7j, middle). 
Interestingly, among the eight down-regulated mRNAs 
belonging to this category, miRWalk 2.0 lists seven as 
predicted (AP1S2, SERP1, RAB10, EDEM1, RAB22A, 
ATP6V1C1 and TNRC6B) and four as validated miR-
204/211 targets (AP1S2, SERP1, EDEM1, RAB22A) 
(Figure 7j, right, Supplementary Table 10). These eight 
genes were further analyzed as described below.
Real-time PCR analysis allowed us to confirm 
that in 501 Mel cells 211-mimic and 204-mimic cause 
the down-regulation of AP1S2, RAB10, RAB22A and 
EDEM1 (Figure 8a). Interestingly, AP1S2, RAB22A and 
EDEM1 have all an established link with TYR. The link 
with AP1S2 and RAB22A (Ras-Related Protein 22A) is 
positive. Specifically, they are involved in the trafficking 
of ATP7A, which in turn is the transporter that provides 
TYR with copper (an essential cofactor for its enzymatic 
activity) [44]. Conversely, the link between EDEM1 
(Endoplasmic Reticulum Degradation Enhancer, 
Mannosidase Alpha-Like 1) and TYR is negative, 
because EDEM1 promotes the retrotranslocation of 
TYR from the ER into the cytoplasm and its subsequent 
degradation through the ER-associated degradation 
(ERAD) pathway [45, 46]. Therefore, we reasoned 
that EDEM1 represents a good fit to explain the post-
transcriptional up-regulation of TYR caused by miR-211 
(miR-211 causes the down-regulation of EDEM1, hence 
the accumulation of TYR protein). The first indication 
that EDEM1 is indeed the mediator of miR-211 pro-
pigmentation activity came from the observation that 
there is a further decrease in its expression levels when 
the over-expression of miR-211 is combined with the 
treatment with vemurafenib (Figure 8b). Furthermore, 
we found that si-EDEM1 is able to recapitulate the 
increase in melanin content (Figure 8c) and the post-
transcriptional increase in TYR levels (Figure 8d, 8e) 
observed after the transfection of 211-mimic. Analogous 
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Figure 7: miR-211 mediates the pro-pigmentation activity of vemurafenib in melanotic melanoma cells. (a) Melanin 
content of 501 Mel cells 96h after the transient transfection of si-CT, 211-mimic or 204-mimic and 72h after the treatment with vehicle 
(DMSO) or 2uM vemurafenib. (b-d) Pictures of 501 Mel cells taken by transmission electron microscopy. (b) i) A representative cell 
transfected with si-CT and treated with DMSO for 72h. ii) A representative cell transfected with si-CT and treated with 2uM vemurafenib 
for 72h, showing mature melanosomes. iii) A representative cell transfected with 211-mimic and treated with DMSO for 72h, showing 
mature melanosomes. iv) A representative cell transfected with 211-mimic and treated with 2uM vemurafenib for 72h, showing abundant 
mature melanosomes. Unpigmented, immature melanosomes are indicated by asterisks (stage I) and white arrows (stage II). Mature 
melanosomes are indicated by arrowheads (stage III) and black arrows (stage IV). n: nucleus; pm: plasma membrane; m: mitochondrion; 
GA: Golgi Apparatus. In all 4 panels, scale bar represents 800 nm. (c-d) Quantification of the total number of melanosomes (c) and of the 
number of stage IV melanosomes (d) upon 72h treatment with 2uM vemurafenib of 501 Mel cells transfected with si-CT or 211-mimic. 
(e) Melanin content in 501 Mel cells 96h after the transient transfection of LNA-CT or LNA-211 and 72h after the treatment with vehicle 
(DMSO) or 2uM vemurafenib. (f-g) TYR RNA (f) and protein levels (g) in 501 Mel cells 96h after the transient transfection of si-CT, 
211-mimic or 204-mimic and 72h after the treatment with vehicle (DMSO) or 2uM vemurafenib. (h-i) TYR RNA (h) and protein levels 
(i) in 501 Mel cells 96h after the transient transfection of LNA-CT or LNA-211 and 72h after the treatment with vehicle (DMSO) or 2uM 
vemurafenib. (j) Schematic representation of the analysis performed on the mRNA array data. The 81 genes showing an overlap between 
those differentially expressed upon the transient transfection of 211-mimic vs si-CT and those differentially expressed upon the transient 
transfection of 204-mimic vs si-CT (left) were subjected to GO enrichment analysis (biological processes), which highlighted the indicated 
categories among the most enriched (p<0.001, middle). The RNAs belonging to these categories and down-regulated (red, top) or up-
regulated (green, bottom) upon 204-mimic and 211-mimic transfection are listed in the heatmap (logFC, right). The graphs represent the 
mean±SEM of 3 independent experiments. *p<0.05, **p<0.01, ***<0.001, ****<0.0001.
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results were obtained by using the chemical inhibition 
of EDEM1 instead of its knock-down. Kifunensine 
(kif), a mannosidase inhibitor known to block EDEM1 
activity and favor the accumulation of TYR [47], is 
able to phenocopy si-EDEM1 (Supplementary Figure 
24). More importantly, we performed two rescue 
experiments that allowed us to demonstrate that miR-
211 exerts its pro-pigmentation activity by acting 
through EDEM1. In Figure 8f-8h we show that the 
concomitant over-expression of the miRNA-insensitive 
ORF of EDEM1 impairs the increase in pigmentation 
caused by 211-mimic. Conversely, in Figure 8i we show 
Figure 8: miR-211 promotes pigmentation by targeting EDEM1. (a) Validation of the array results. Expression levels of the 
mRNAs selected through GO enrichment analysis and measured 24h after the transient transfection of si-CT (white), 204-mimic (red) or 
211-mimic (blue). (b) Effects of the transfection with 211-mimic and the treatment with 2uM vemurafenib on the levels of the indicated 
mRNAs. Vemurafenib was added 24h after the transfection and cell pellets were collected after additional 48h. (c-e) Melanin content (c), 
EDEM1 and TYR mRNA levels (d) and TYR protein levels (e) in 501 Mel cells transfected with si-CT or si-EDEM1 and then treated with 
2uM vemurafenib for 72h. (f-h) Melanin content (f), EDEM1 and TYR mRNA levels (g) and TYR protein levels (h) in 501 Mel cells stably 
infected with an empty lentiviral vector or a lentiviral vector expressing the miRNA-insensitive EDEM1 ORF, then transfected with si-CT 
or 211-mimic and finally treated with 0.5uM vemurafenib for 48h. (i) Melanin content in 501 Mel transiently transfected with si-CT and 
LNA-CT or LNA-211, or with si-EDEM1 and LNA-CT or LNA-211. 24h after the transfection the cells were treated with DMSO or 2uM 
vemurafenib for 72h. The graphs represent the mean±SEM of 3 independent experiments. *p<0.05, **p<0.01, ***<0.001.
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that the impairment in pigmentation that occurs when 
endogenous miR-211 is inhibited by the LNA is strongly 
reduced by the concomitant knock-down of EDEM1.
All together, these results indicate that, in melanotic 
melanoma cells, miR-211 is induced by BRAFi/MEKi 
and favors their pro-pigmentation activity by targeting 
EDEM1, hence promoting TYR expression and melanin 
accumulation. Next, we investigated whether pigmentation 
affects the sensitivity of melanotic melanoma cells to 
BRAFi/MEKi.
Pigmentation limits the efficacy of BRAFi/MEKi
It has been recently shown that, by blocking the 
ERK pathway, vemurafenib disrupts the cytoplasmic 
production of ATP through anaerobic glycolysis. At 
the same time, the loss of MITF repression with the 
consequent induction of PGC1alpha and mitochondrial 
biogenesis force melanoma cells to switch back to 
oxidative phosphorylation. This in turn is an adaptive 
response that de facto limits vemurafenib activity by 
providing the cells with an alternative bioenergetic way 
to survive [3, 4]. On the other hand, it is known that 
melanosomes can sequester drugs and release them outside 
the cells, therefore contributing to melanoma multidrug 
resistance (MDR) [39, 48]. On the basis of this evidence, 
we hypothesized that in melanotic melanoma cells the 
activity of BRAFi/MEKi is limited not only by oxidative 
phosphorylation, but also by pigmentation.
A first indication in support of our hypothesis came 
from the analysis of the GSE 19234 dataset of metastatic 
melanoma patients: similarly to what has been reported for 
PGC1alpha levels [3], we found that metastatic melanoma 
patients with high TRPM1/EDEM1 ratio are characterized 
by lower overall survival compared to those with low 
TRPM1/EDEM1 ratio (Figure 9a and Supplementary 
Figure 25-27; see also ref [49]). In ref [28], Cirenajwis 
and colleagues report similar results: metastatic patients 
with high “MITF signature” (i.e. high expression of 
melanocyte-associated genes) display worse prognosis.
We also found that on average melanotic cell 
lines display higher IC50 to vemurafenib and trametinib 
compared to amelanotic cell lines (Figure 9b).
Finally, although indications already exist that 
individual metastatic melanoma patients with melanotic 
tumors respond poorly to BRAFi/MEKi treatment [28], 
we tested a cohort composed of 77 metastatic melanoma 
patients [26 with amelanotic tumors and 51 with melanotic 
tumors], all treated with BRAFi or combined BRAFi/
MEKi therapy at New York University (NYU) Langone 
Medical Center from 2002 to 2015 (Supplementary Table 
11). Patients were divided into two groups based on 
their responsiveness to targeted therapy: non-responders 
(Progression of Disease) and responders (Stable Disease, 
Partial Response, and Complete Response). Analysis 
showed that patients with melanotic metastases were 
significantly more likely to be non-responders to targeted 
therapy compared to patients with amelanotic metastases 
(Figure 9c).
Next, we aimed at providing experimental evidence 
that pigmentation negatively affects the activity of 
BRAFi and MEKi. We reasoned that, if our hypothesis 
was correct, then the over-expression/inhibition of the 
pro-pigmentation miR-211 should confer melanotic cells 
a decreased/increased sensitivity to vemurafenib. Since 
both vemurafenib and miR-211 are known to exert non 
cell-autonomous functions [50, 51], we decided to test 
our hypothesis in the in vivo setting. 501 Mel cells that 
stably over-express miR-CT or miR-211 were injected 
into the yolk sac of zebrafish embryos and treated 
with vemurafenib. When we measured the mass of the 
xenografted tumors, we did obtain results that are in 
agreement with our hypothesis: miR-211 over-expression 
causes per se a decrease in cell proliferation (compare 
the first and the third column in Figure 9d). However, 
it prevents vemurafenib from working (compare the 
first vs the second and the third vs the fourth column in 
Figure 9d). Consistently, the inhibition of endogenous 
miR-211 causes per se an increase in cell proliferation 
(compare the first and the third column in Figure 9e), 
but favors vemurafenib activity (compare the first vs 
the second and the third vs the fourth column in Figure 
9e). The effects exerted by miR-211 on proliferation and 
sensitivity to vemurafenib depend on its pro-pigmentation 
activity, as demonstrated by the fact that they are 
reverted by the concomitant treatment with an inhibitor 
of melanin biosynthesis such as N-phenylthiourea (PTU) 
(Supplementary Figure 28a, 28b). We also found that in 
vitro the LNA-mediated inhibition of endogenous miR-
211, although ineffective per se (Supplementary Figure 
29), cooperates with PTU in increasing the sensitivity 
of 501 Mel to vemurafenib (Supplementary Figure 30a). 
Analogous results were obtained in another melanotic cell 
line (SK-Mel-5, Supplementary Figure 30b).
The enhancement in the sensitivity of melanotic 
melanoma cells to vemurafenib by the concomitant 
inhibition of pigmentation was investigated further 
using synthetic drugs. In Figure 9f we used the graft in 
zebrafish embryos to show that the sensitivity of 501 Mel 
to vemurafenib is increased by the concomitant treatment 
with PTU. Finally, we assessed whether the efficacy of 
vemurafenib is improved even further when the adaptive 
responses that it elicits are both inhibited at the same time, 
which is to say when it is administered in combination not 
only with an inhibitor of pigmentation such as PTU but 
also with an inhibitor of oxidative phosphorylation such 
as oligomycin. Interestingly, the rationale for testing the 
combination of vemurafenib plus PTU and/or oligomycin 
relies also on the fact that, by targeting PDK4, miR-
211 itself promotes mitochondrial biogenesis/oxidative 
phosphorylation as well [52]. Indeed, when we treated 501 
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Mel cells (Figure 9g) or SK-Mel-5 (Supplementary Figure 
31a) with IC25 concentrations of vemurafenib, PTU and 
oligomycin, we found that both PTU and oligomycin can 
potentiate the activity of vemurafenib (see above and ref 
[3]). However, the effects are even stronger when all three 
of them are administered together. These results were also 
confirmed in vivo in our xenograft model (Figure 9h, 9i). 
Interestingly, when we performed the same experiments 
in the amelanotic cell line A375, we found that PTU 
is not effective per se, nor can potentiate the effects of 
vemurafenib and oligomycin (Supplementary Figure 31b), 
which further indicates that the increase in pigmentation 
is an additional adaptive response that limits vemurafenib 
effects only in melanotic cells.
DISCUSSION
In this work, we show that in melanoma cells 
BRAFV600E negatively regulates miR-204 and miR-211 
through the ERK pathway. We also show that, despite 
Figure 9: Pigmentation impairs the activity of BRAFi and MEKi. (a) Above the median (blue) and below the median (black) 
TRPM1/EDEM1 ratios allow to stratify metastatic melanoma patients according to their overall survival (GSE 19234). (b) IC50 of melanotic 
and amelanotic melanoma cell lines treated with vemurafenib (BRAFV600 E or K) and trametinib (BRAFV600 E or K, wt BRAF). (c) 
Response of 51 metastatic melanoma patients with melanotic tumors and 26 metastatic melanoma patients with amelanotic tumors to 
treatment with BRAFi or combined BRAFi/MEKi. Patients showing disease progression upon treatment were classified as non-responders, 
while patients showing stable disease, partial response or complete response upon treatment were classified as responders. The Fisher Exact 
Probability Test indicate that patients with melanotic metastases are significantly more likely to be non-responders to targeted therapy 
compared to patients with amelanotic metastases (p=0.045) (d) 501 Mel cells that stably over-express a control miRNA (p-miR-CT, white and 
black) or miR-211 (p-miR-211, blue and dark blue) were treated with DMSO or 2uM vemurafenib for 48h. They were then injected into the 
yolk sac of 48hfp zebrafish embryos. The masses of the xenografted tumors were measured 48h later. (e) 501 Mel cells transiently transfected 
with LNA-CT (white and black), or LNA-211 (blue and dark blue) were treated with DMSO or 2uM vemurafenib for 48h. They were then 
injected into the yolk sac of 48hpf zebrafish embryos. The masses of the xenografted tumors were measured 48h later. (f) 501 Mel cells were 
treated with DMSO (white), 0.2uM vemurafenib (black), 0.1uM PTU (blue) or 0.2uM vemurafenib plus 0.1uM PTU (dark blue) for 48h. 
They were then injected into the yolk sac of 48hpf stage zebrafish embryos. The masses of the xenografted tumors were measured 48h later. 
(Continued )
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belonging to the same family, these two miRNAs have 
distinct features: i) they are under the control of different 
transcription factors (STAT3 for miR-204 and MITF for 
miR-211); ii) they are induced in different cellular contexts 
(miR-204 in amelanotic and miR-211 in melanotic 
cells); iii) they have different mechanisms of action; iv) 
their relationship with vemurafenib varies. Namely, by 
targeting AP1S2 in amelanotic cells, miR-204 mediates 
and potentiates the anti-motility effects of vemurafenib. 
Conversely, by targeting EDEM1 in melanotic cells, miR-
211 mediates and potentiates the increase in pigmentation 
elicited by vemurafenib, which in turn represents an 
adaptive response that de facto limits its efficacy as a drug 
(Figure 9j)
Our study brings miR-204 to the forefront 
and defines the oncosuppressive role that it plays in 
melanoma, in spite of the fact that it is less abundant than 
miR-211 [17, 25–28, 53, 54]. Until now, only miR-211 
had been shown to inhibit the in vitro and in vivo motility 
of melanoma cells, by means of its over-expression 
in cell lines that do not express it [18] or express it at 
very low levels [55]. Here, we show that miR-204 is as 
effective as miR-211 at inhibiting the migration/invasion 
of melanoma cells and, more importantly, that it exerts 
such an activity in the cellular contexts in which miR-
211 is absent. Notably, the TRPM3/miR-204 locus does 
not undergo genomic loss like that of many classical 
oncosuppressors. Nonetheless, TRPM3/miR-204 levels 
are lower in nevi compared with melanoma samples [17, 
25, 27]. Furthermore, we found that a high TRPM3/AP1S2 
ratio correlates with higher overall survival in metastatic 
melanoma samples (Figure 6f), a trend that reaches 
statistical significance when we consider the ratio 
between TRPM3/AP1S2 and TRPM1/EDEM1, or the 
TRPM3/TRPM1 ratio, which equals to say when we 
consider the subset of patients with high TRPM3/miR-204 
and low TRPM1/miR-211 levels (Supplementary Figure 
21).
The melanocytic lineage-specific and MITF-
regulated miR-211 is invariably down-regulated and 
frequently lost [56–58] or epigenetically silenced [59] 
in melanoma samples (a decrease in its expression levels 
Figure 9 (Continued ): (g) Cell number upon the treatment of 501 Mel cells with 0.1uM vemurafenib, 0.5uM PTU and 0.01uM 
oligomycin (OM) or their combinations for one week. (h-i) 501 Mel cells were treated with DMSO (white), 0.1uM vemurafenib plus 0.5uM 
PTU, 0.1uM vemurafenib plus 0.01uM oligomycine or 0.1uM vemurafenib plus 0.5uM PTU plus 0.01uM oligomycine (dark grey) for 48h. 
They were then injected into the yolk sac of 48hpf zebrafish embryos. (h) The masses of the xenografted tumors were measured 48h later. 
(i) Representative pictures of the tumor masses. (j) Cartoon that summarizes the main findings of this article. miR-204 and miR-211 are 
negatively regulated by BRAFV600E through the ERK pathway and are under the transcriptional control of STAT3 and MITF, respectively. 
By targeting AP1S2, miR-204 is the mediator of the anti-motility activity exerted by vemurafenib on amelanotic cells. Conversely, by 
targeting EDEM1 and hence preventing TYR degradation through the ERAD pathway, miR-211 is the mediator of the pro-pigmentation 
activity exerted by vemurafenib on melanotic cells. Such an activity in turn limits the efficacy of vemurafenib itself. The graphs represent 
the mean±SEM of 3 independent experiments. *p<0.05, **p<0.01, ***<0.001, ***<0.001.
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is enough to distinguish nevi from melanomas [17, 
60]). Furthermore, its ability to inhibit the proliferation 
and, mainly, the motility of melanoma cells has been 
extensively demonstrated in vitro [18, 55, 56, 61] and 
in animal models (see Figure 9d, 9e and also ref [62]). 
Nevertheless, our study uncovers novel and highly 
relevant aspects of miR-211 biology, as listed below.
First, our data grant the inclusion of miR-211 in 
the group of miRNAs that thus far have been shown 
to affect pigmentation, by either promoting (miR-203 
[63]) or impairing (miR-125b [64] and miR-145 [65]) 
its production. The protective effects exerted on TYR 
by miR-211 through the down-regulation of EDEM1 
conceptually similar to those exerted by miR-203 
through the down-regulation of KIF5B [63]. Interestingly, 
although miR-203 displays a much higher p-value 
compared to miR-204 and miR-211, it is still among the 
top-scoring miRNAs that are consistent with the signature 
of modulated mRNAs that we obtained in our mRNA 
array (Supplementary Figure 23b, 23c).
Second, our data help explaining the observation that 
the shRNA-mediated down-regulation of TRPM1 causes a 
decrease in TYR protein but not mRNA levels [66]. Since 
the splicing of TRPM1 pre-mRNA and the maturation of 
pri-miR-211 have been shown to reinforce each other [67], 
we can speculate that the effect observed upon TRPM1 
down-regulation is in fact due to the decrease in mature 
miR-211 levels. The anti-motility activity exerted by 
TRPM1/miR-211 has been itself attributed mostly to the 
miRNA [18].
Third, we provide a molecular mechanism 
explaining the increase in pigmentation that has been 
associated with vemurafenib and generally attributed to 
an increase in MITF activity [3].
The novel findings about miR-204 and miR-211 that 
we report in our study are important both in terms of basic 
miRNA biology and at the translational level.
The differences uncovered between these two 
miRNAs allow us to challenge the “same miRNA family 
= same function” rule. The molecular data shown in 
Figure 6a, Figure 7f, 7g and Figure 8a and the cellular 
assays shown in Figure 5a-5d and Figure 7a indicate that 
miR-204 and miR-211 target highly overlapping pools of 
genes and that they exert similar activities (anti-motility 
and pro-pigmentation), a finding that is expected from 
miRNAs belonging to the same family. However, we 
also demonstrate that it is the cellular context in which 
the endogenous miRNAs are induced that ultimately 
defines their function. Specifically, we show that 
miR-204 is induced in amelanotic cells, a context in 
which the absence of a functional melanin biosynthetic 
pathway makes it impossible to exert a pro-pigmentation 
activity. In particular, A375 cells lack the expression 
of TYR, the very protein whose accumulation is at the 
basis of the increase in melanin content. Therefore, 
although miR-204 in principle is able to target EDEM1 
(Supplementary Figure 32), in this cellular context it can 
only exert its anti-motility activity. Conversely, miR-211 
is induced in melanotic cells that have high expression of 
MITF/TRPM1/miR-211 and, consistently, limited basal 
migratory ability (501 Mel do not migrate in the wound 
healing assay; see also ref [18]). Therefore, although miR-
211 is in principle able to target AP1S2 (Figure 8a), in 
this cellular context it can only exert its pro-pigmentation 
activity. In other words, the data suggest that the inability 
of miR-204 to increase the pigmentation of amelanotic 
cells, as well as the inability of miR-211 to decrease the 
motility of melanotic cells, is attributable to the cellular 
environment and not to the fact that they cannot down-
regulate their relevant targets. In turn, this suggests that 
the final activity of a given miRNA certainly depends 
on the identity of its target genes and its intrinsic ability 
to down-regulate them [68]. However, it also depends 
on other factors that lay both upstream and downstream 
from the mere miRNA/target interactions, such as the 
transcription factors that regulate its expression level and 
the overall status of the cellular pathways to which the 
targets belong.
The study of miR-211 in melanotic melanoma 
cells has allowed us to demonstrate that it is part of the 
“normalization program” triggered by the inhibition of 
the ERK pathway: the consequent derepression of MITF 
promotes not only a switch from glycolysis to oxidative 
phosphorylation through PGC1alpha and mitochondrial 
biogenesis [3, 69], but also a more differentiated 
phenotype through TRPM1/miR-211 and the melanin 
biosynthetic pathway. We also show that this “adaptive 
response” limits the effectiveness of ERK pathway 
inhibitors and needs to be overcome by the concomitant 
treatment with pigmentation inhibitors in order to unleash 
their full potential. These findings have important 
therapeutic implications, as explained below.
First, they support the double role played by MITF 
in the melanocytic lineage. MITF is the master regulator 
of the melanocyte differentiation program, therefore on 
one side it acts as a tumor suppressor, but on the other side 
it allows the retreat of melanoma cells into a “functional 
niche” in which they are protected from vemurafenib, 
hence it confers drug resistance [3, 4, 70–72].
In addition, our findings allow reconciling the 
apparent paradox that is associated with TRPM1/miR-
211 behavior in melanoma: as mentioned above, in the 
transition from nevi to primary melanoma TRPM1/miR-
211 levels are very often down-regulated or lost [56–
58]. Furthermore, in primary melanoma patients high 
TRPM1 levels correlate with longer disease free survival 
(DFS) [73, 74]. In contrast, in metastatic melanoma, 
where TRPM1/miR-211 levels do not show a further 
decrease compared to patients with primary melanoma 
[26, 53, 57, 75], the patients associated with longer OS 
are those with low TRPM1 levels (Supplementary Figure 
25-27).
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Finally, our findings offer a rationale for testing new 
combinatorial therapeutic strategies. The data reported 
in Figure 9 warrant to assess if the melanotic status 
can be considered a predictive biomarker of response 
to BRAFi/MEKi, as the first example in this field [76]. 
Going forward, an important study would be to investigate 
whether metastatic patients with melanotic tumors 
respond better to the combination of BRAFi/MEKi with 
pigmentation inhibitors rather than to BRAFi/MEKi alone 
[76]. A limiting factor might be the choice of the right 
pigmentation inhibitor. Currently these drugs are used 
only topically for the treatment of hyper-pigmentation 
disorders). However, they block pigmentation at different 
levels [77] and there might be some that are compatible 
with systemic administration. In addition, our findings 
warrant studies examining whether the efficacy of 
BRAFi/MEKi on melanotic melanoma patients is further 
increased when not only pigmentation inhibitors, but also 
inhibitors of oxidative phosphorylation/mitochondrial 
biogenesis are added to the treatment regimen. It is 
important to keep in mind that all such testing should be 
performed on therapy-naïve patients that receive their first 
line of treatment. The reactivation of the ERK pathway 
that occurs in the vast majority of relapsing tumors brings 
PGC1alpha and TRPM1/miR-211 back to basal levels and 
prevents their induction upon BRAFi/MEKi treatment ([3] 
and Figure 3). Therefore, it blunts the adaptive responses 
that are at the basis of the cooperation between BRAFi/
MEKi themselves and the inhibitors of pigmentation/
mitochondrial functioning.
In conclusion, our work highlights the importance 
of the study of the non-protein coding genes that are 
regulated by BRAFV600E through the ERK pathway, 
since they can contribute to a deeper understanding of 
BRAFV600E biology and of the functioning of BRAF 
inhibitors. This in turn can lead to novel strategies for the 
improvement of the still suboptimal therapeutic options 
available for metastatic melanoma patients [9].
MATERIALS AND METHODS
Cell culturing, as well as cellular assays (transient 
transfections, stable infections, growth curve, cell cycle 
analysis, clonogenicity assay, soft agar assay, limiting 
dilution assay, co-colture assay, migration assay, invasion 
assay, melanin content evaluation) and molecular assays 
(PCR, real-time PCR, western blot) were performed 
according to standard procedures, which are described in 
details in Supplementary Materials and Methods. In vivo 
experiments were performed in compliance of protocols 
approved by the Italian Ministry of Health. Details on 
the experimental procedures followed are reported in 
Supplementary Materials and Methods. The same file 
contains details on transmission electron microscope 
analysis, on the execution and the analysis of miRNA-seq 
and mRNA array, as well as on correlation analysis, seed 
enrichment analysis, miRNA target enrichment analysis 
and on the analysis of metastatic melanoma sample 
datasets.
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